Westside Investment Management Inc. Has $7.66 Million Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Westside Investment Management Inc. reduced its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 7.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 575,222 shares of the company’s stock after selling 43,453 shares during the quarter. Eton Pharmaceuticals comprises 1.6% of Westside Investment Management Inc.’s holdings, making the stock its 12th largest holding. Westside Investment Management Inc.’s holdings in Eton Pharmaceuticals were worth $7,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in ETON. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eton Pharmaceuticals in the third quarter worth approximately $54,000. Jane Street Group LLC bought a new stake in Eton Pharmaceuticals in the third quarter worth approximately $90,000. Renaissance Technologies LLC increased its holdings in Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Eton Pharmaceuticals in the second quarter worth approximately $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares in the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ETON. B. Riley assumed coverage on Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 target price for the company. HC Wainwright boosted their price objective on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, January 6th. Finally, Craig Hallum boosted their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, January 8th.

Eton Pharmaceuticals Trading Up 5.3 %

Shares of Eton Pharmaceuticals stock opened at $15.18 on Wednesday. The stock has a fifty day simple moving average of $12.51 and a 200 day simple moving average of $8.02. Eton Pharmaceuticals, Inc. has a 12-month low of $3.03 and a 12-month high of $15.71. The company has a market capitalization of $395.39 million, a P/E ratio of -69.41 and a beta of 1.38.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.